<DOC>
	<DOCNO>NCT00957385</DOCNO>
	<brief_summary>The purpose study determine Revlimid help maintain patient acute myeloid leukemia remission .</brief_summary>
	<brief_title>Maintenance Therapy Acute Myeloid Leukemia ( AML ) Patients</brief_title>
	<detailed_description>At present , majority AML patient &gt; 60 year age achieve CR thereafter successfully complete chemotherapy , candidate allogeneic bone marrow transplantation ( alloBMT ) due age . Rather , group patient simply observe relapse occurs . In age group , median duration CR ~10 month . The survival patient &lt; 60 year age candidate transplantation ( due donor unavailability ) , CR2 high also extremely poor . Several line evidence suggest immune system - particular AML specific CTLs NK cell - capable recognize clear AML cell .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Diagnosis Acute myeloid leukemia remission . Able take aspirin 81mgs daily . Pregnant breast feeding female . Known hypersensitivity thalidomide . Any prior use lenalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Remission</keyword>
</DOC>